Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 8/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL210422 | 0.82 | EPHX2 (0.71) | GRIN2BCYP2D6EPHX2POLBKDM4E | |
| SCHEMBL5352863 | 0.81 | GRIN2B (1.00) | GRIN2BCYP2D6 | |
| SCHEMBL3449454 | 0.79 | MEN1 (0.46) | GRIN2BCYP2D6EPHX2KDM4EMAPT | |
| SCHEMBL20508546 | 0.77 | GRIN2B (0.67) | GRIN2B | |
| SCHEMBL13493665 | 0.74 | GRIN2B (0.46) | GRIN2BCYP2D6EPHX2POLBMAPT | |
| SCHEMBL12806994 | 0.74 | GRIN2B (0.46) | GRIN2BEPHX2POLB | |
| SCHEMBL4427585 | 0.74 | ALDH1A1 (0.48) | GRIN2BPOLBKDM4EMAPTGAA | |
| SCHEMBL20775269 | 0.73 | GRIN2B (0.66) | GRIN2BCYP2D6EPHX2 | |
| SCHEMBL3903559 | 0.73 | SMN1; SMN2 (0.45) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1582298 | 0.72 | CHRM5 (0.41) | GRIN2BCYP2D6POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534887-B2 | Thiazoline derivative and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20070010528-A1 | Thiazoline derivative and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1669352-A1 | THIAZOLINE DERIVATIVE AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010528-A1 | Thiazoline derivative and use of the same | TBXA2R, F2, F3 | GRIN2B 1723/4885CYP2D6 129/4885EPHX2 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.